272 related articles for article (PubMed ID: 10230677)
1. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
[TBL] [Abstract][Full Text] [Related]
2. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
Aro J; Ruutu M; Juusela H; Hansson E; Permi J
Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E;
J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
[TBL] [Abstract][Full Text] [Related]
4. [Hormonal therapy (medical orchiectomy) in prostatic carcinoma].
Studer UE; Münch D
Schweiz Med Wochenschr; 1990 Jun; 120(24):881-7. PubMed ID: 2193381
[TBL] [Abstract][Full Text] [Related]
5. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
Lindstedt E
Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
[TBL] [Abstract][Full Text] [Related]
6. [The potential hormonal therapy of prostatic carcinoma].
Studer UE; Altwein J; Bartsch G
Urologe A; 1991 Sep; 30(5):310-6. PubMed ID: 1949440
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
8. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
[TBL] [Abstract][Full Text] [Related]
9. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
[TBL] [Abstract][Full Text] [Related]
10. [What is safe in the therapy of advanced prostatic cancer?].
Gropp C; Burk K
Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
[No Abstract] [Full Text] [Related]
11. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO; Ala-Opas M; Brekkan E; Damber JE; Damber L; Hagerman I; Haukaas S; Henriksson P; Iversen P; Pousette A; Rasmussen F; Salo J; Vaage S; Varenhorst E;
Scand J Urol Nephrol; 2002; 36(6):405-13. PubMed ID: 12623503
[TBL] [Abstract][Full Text] [Related]
12. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
13. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Hedlund PO; Henriksson P
Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
[TBL] [Abstract][Full Text] [Related]
14. Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer.
Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
Scand J Urol Nephrol Suppl; 1988; 110():103-7. PubMed ID: 3187397
[TBL] [Abstract][Full Text] [Related]
15. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
16. Hormonal therapy of prostate cancer: current concepts and future prospects.
Smith JA
Clin Ther; 1988; 10(3):281-6. PubMed ID: 3078908
[TBL] [Abstract][Full Text] [Related]
17. Complete androgen blockade for the treatment of prostate cancer.
Labrie F; Dupont A; Belanger A
Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
[No Abstract] [Full Text] [Related]
18. re: Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. R. Haapiainen et al. Br. J. Urol., 66, 94-97, 1990.
Bishop MC
Br J Urol; 1991 Aug; 68(2):218. PubMed ID: 1884161
[No Abstract] [Full Text] [Related]
19. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
20. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy.
Mikkola A; Aro J; Rannikko S; Ruutu M;
Prostate; 2007 Mar; 67(4):447-55. PubMed ID: 17219379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
